Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy (SWOG S0715) (2013)

Peer-Reviewed Study · Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, et al. · July 10, 2013

Hershman DL et al., 2013-07-10: Randomised double-blind trial in 409 women receiving adjuvant taxane chemotherapy, comparing acetyl-L-carnitine 3,000 mg/day with placebo. ALC did not prevent neuropathy and made it worse by 24 weeks.

There was no evidence that ALC affected CIPN at 12 weeks; however, ALC significantly increased CIPN by 24 weeks. This is the first study to our knowledge showing that a nutritional supplement increased CIPN.

Abstract (Conclusion)

Hershman DL et al., 2013-07-10: Randomised double-blind trial in 409 women receiving adjuvant taxane chemotherapy, comparing acetyl-L-carnitine 3,000 mg/day with placebo. ALC did not prevent neuropathy and made it worse by 24 weeks. Funder: SWOG/NCI cooperative group trial (NCT00075491); authors' disclosures published with the article, full text not read this run. Comparator: placebo. Maker: ALC is a supplement, not a marketed drug; no manufacturer sponsorship identified. Grade 3-4 neurotoxicity was more frequent on ALC (8 vs 1). Study type: randomized trial.